[go: up one dir, main page]

AR128257A1 - Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting - Google Patents

Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting

Info

Publication number
AR128257A1
AR128257A1 ARP230100077A ARP230100077A AR128257A1 AR 128257 A1 AR128257 A1 AR 128257A1 AR P230100077 A ARP230100077 A AR P230100077A AR P230100077 A ARP230100077 A AR P230100077A AR 128257 A1 AR128257 A1 AR 128257A1
Authority
AR
Argentina
Prior art keywords
compositions
compounds
compound
pharmaceutically acceptable
conditions related
Prior art date
Application number
ARP230100077A
Other languages
English (en)
Inventor
Shankar Venkatraman
Jason Katz
William R Roush
Hans Martin Seidel
Original Assignee
Ifm Due Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifm Due Inc filed Critical Ifm Due Inc
Publication of AR128257A1 publication Critical patent/AR128257A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de la fórmula (1). Reivindicación 25: Una composición farmacéutica caracterizada porque comprende un compuesto de una cualquiera de las reivindicaciones 1 a 24 o una sal farmacéuticamente aceptable de este y excipientes farmacéuticamente aceptables. Reivindicación 26: Un método para inhibir la actividad de STING, el método comprende el contacto de STING con un compuesto conforme se reivindica en una cualquiera de las reivindicaciones 1 a 24, o una sal farmacéuticamente aceptable de este; o una composición farmacéutica conforme se reivindica en la reivindicación 25. Reivindicación 27: Un método para inducir una respuesta inmunitaria en un sujeto que necesita de esta, el método comprende administrar al sujeto una cantidad eficaz de un compuesto conforme se reivindica en una cualquiera de las reivindicaciones 1 a 24, o una sal farmacéuticamente aceptable de este; o una composición farmacéutica conforme se reivindica en la reivindicación 25.
ARP230100077A 2022-01-12 2023-01-12 Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting AR128257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263298987P 2022-01-12 2022-01-12

Publications (1)

Publication Number Publication Date
AR128257A1 true AR128257A1 (es) 2024-04-10

Family

ID=85222039

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100077A AR128257A1 (es) 2022-01-12 2023-01-12 Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting

Country Status (8)

Country Link
US (1) US20230250060A1 (es)
EP (1) EP4463442A1 (es)
JP (1) JP2025503675A (es)
CN (1) CN118613473A (es)
AR (1) AR128257A1 (es)
TW (1) TW202334084A (es)
UY (1) UY40106A (es)
WO (1) WO2023137034A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117529475A (zh) 2021-01-08 2024-02-06 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的含脲或类似物的杂双环化合物及其化合物
KR20240056718A (ko) * 2021-08-10 2024-04-30 아이에프엠 듀, 인크. Sting 활성과 연합된 상태를 치료하기 위한 화합물 및 조성물
WO2025079045A1 (en) * 2023-10-12 2025-04-17 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU662997B2 (en) * 1992-07-03 1995-09-21 Ihara Chemical Industry Co. Ltd. Condensed heterocyclic derivative and weedkiller
PL368347A1 (en) * 2001-09-26 2005-03-21 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CA2693901C (en) * 2007-07-20 2015-12-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
US8497285B2 (en) 2010-12-03 2013-07-30 The Trustees Of The University Of Pennsylvania Therapy of autoimmune colitis using a TIP60 inhibitor
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
US9642830B2 (en) 2013-10-21 2017-05-09 Drexel University Use of sting agonists to treat hepatitis B virus infection
TW202043198A (zh) * 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
JP2023540674A (ja) * 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2022140410A1 (en) * 2020-12-22 2022-06-30 Ifm Due, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
CN118613473A (zh) 2024-09-06
WO2023137034A1 (en) 2023-07-20
TW202334084A (zh) 2023-09-01
US20230250060A1 (en) 2023-08-10
JP2025503675A (ja) 2025-02-04
UY40106A (es) 2023-08-15
EP4463442A1 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
AR128257A1 (es) Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting
MX2023007192A (es) Inhibidores de prmt5.
MX2022011748A (es) Composiciones orales de inhibidor de ruta de mk2 para el tratamiento de condiciones inmunitarias.
PE20242299A1 (es) Composiciones agonistas de gip/glp1
AR128499A1 (es) Inhibidores de parg
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
SG11201805791RA (en) COMPOSITION FOR INCREASING EXPRESSION OF PGC-1α
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
MX2022011240A (es) Azálidos de urea inmunomoduladores.
MX2022010394A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
PE20220486A1 (es) Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico
CO2026000093A2 (es) Composiciones farmacéuticas para inhibidores de la cinasa nek7
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
BR112022007616A2 (pt) Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763)
AR129959A1 (es) Método para tratar enfermedades o trastornos orgánicos con inhibidores de ask1
MX2023009620A (es) Metodos terapeuticos.
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
CL2023000648A1 (es) Métodos para tratar enfermedades o afecciones mediadas por pde iv
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
UY39466A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis